Report Summary

Market Performance:

On April 14, 2025, the pharmaceutical sector rose and fell by +1.04%, outperforming the CSI 300 Index by 0.81 pct, ranking 18th among the 31 sub-sectors of Shenwan. Among the pharmaceutical sub-sectors, other biological products (+1.90%), medical R&D outsourcing (+1.43%), and in vitro diagnostics (+0.84%) performed first, while medical equipment (-0.28%), blood products (+0.33%), and vaccines (+0.34%) performed second. In terms of individual stocks, the top 3 daily gainers are Yuekang Pharmaceutical (+19.99%), Poinsettia (+19.30%), and Sinovac Pharmaceutical (+16.83%); The top 3 decliners were Haisco (-4.28%), Yirui Technology (-3.71%), and Huada Manufacturing (-3.48%).

Industry news:

On April 14, the official website of the State Food and Drug Administration (NMPA) of China formulated that the new drug Pemafibrate developed by Kowa Company was officially approved in China, and the approved indication is the treatment of dyslipidemia. It is a novel peroxisome proliferator-activated receptor (PPAR)α agonist. In terms of mechanism of action, it binds to PPARα and regulates the expression of genes involved in lipid metabolism, thereby reducing plasma triglyceride (TG) levels and increasing high-density lipoprotein cholesterol (HDLC) levels to achieve the purpose of lipid lowering.



Company news:

Novo Zhiyuan (688315): The company released the first quarter report of 2025, the company achieved operating income of 502 million yuan, a year-on-year increase of 7.16%, a net profit attributable to the parent company of 34 million yuan, a year-on-year increase of 24.02%, and a net profit attributable to the parent company of 25 million yuan, a year-on-year increase of 17.80%.

Jiuzhou Pharmaceutical (603456): The company released the first quarter report of 2025, the company achieved operating income of 1.490 billion yuan, a year-on-year increase of 0.98%, net profit attributable to the parent company of 250 million yuan, a year-on-year increase of 5.68%, and net profit attributable to the parent company after deducting non-profit of 251 million yuan, a year-on-year increase of 7.17%.

Luoxin Pharmaceutical (002793): The company released a performance forecast for the first quarter of 2025, and the company expects the net profit attributable to the parent company to be 5 million to 7 million yuan, a loss of 36.6616 million yuan in the same period last year, and a net profit of 50-700,000 yuan after deducting non-profits, and a loss of 38.956 million yuan in the same period last year.

Nanwei Medical (688029): The company announced that Mr. Long Xiaohui, chairman of the company, proposed to repurchase the company's shares with the company's free funds, with a repurchase amount of 30 million to 50 million yuan, and the repurchase price should not exceed 150% of the average trading price of the company's shares in the 30 trading days before the board of directors' resolution, and the repurchase was used for equity incentives or employee stock ownership plans.

Risk warning: the R&D and marketing of new drugs are less than expected; market competition intensifies, risks, etc.